Abstract
Targeting nanomedicine to brain tumors is hampered by the heterogeneity of brain tumors and the blood brain barrier. These represent the main reasons of unsuccessful treatments. Nanomedicine based approaches hold promise for improved brain tissue distribution of drugs and delivery of combination therapies. In this review, we describe the recent advancements and latest achievements in the use of nanocarriers, virus and cell-derived nanoparticles for targeted therapy of brain tumors. We provide successful examples of nanomedicine based approaches for direct targeting of receptors expressed in brain tumor cells or modulation of pathways involved in cell survival as well as approaches for indirect targeting of cells in the tumor stroma and immunotherapies. Although the field is at its infancy, clinical trials involving nanomedicine based approaches for brain tumors are ongoing and many others will start in the near future.
Keywords: Nanomedicine, brain tumor, nanoparticles, glioblastoma multiforme, convection enhanced delivery (CED), dendrimers, nanoprodrugs, exosomes, viruses.
Current Pharmaceutical Design
Title:Targeting Nanomedicine to Brain Tumors: Latest Progress and Achievements
Volume: 23 Issue: 13
Author(s): Moniek van ‘t Root, Clemens Löwik and Laura Mezzanotte*
Affiliation:
- Optical Molecular Imaging, Department of Radiology, Erasmus Medical Center, 's-Gravendijkwal 230, 3015 CE Rotterdam,,Netherlands
Keywords: Nanomedicine, brain tumor, nanoparticles, glioblastoma multiforme, convection enhanced delivery (CED), dendrimers, nanoprodrugs, exosomes, viruses.
Abstract: Targeting nanomedicine to brain tumors is hampered by the heterogeneity of brain tumors and the blood brain barrier. These represent the main reasons of unsuccessful treatments. Nanomedicine based approaches hold promise for improved brain tissue distribution of drugs and delivery of combination therapies. In this review, we describe the recent advancements and latest achievements in the use of nanocarriers, virus and cell-derived nanoparticles for targeted therapy of brain tumors. We provide successful examples of nanomedicine based approaches for direct targeting of receptors expressed in brain tumor cells or modulation of pathways involved in cell survival as well as approaches for indirect targeting of cells in the tumor stroma and immunotherapies. Although the field is at its infancy, clinical trials involving nanomedicine based approaches for brain tumors are ongoing and many others will start in the near future.
Export Options
About this article
Cite this article as:
Root van ‘t Moniek , Löwik Clemens and Mezzanotte Laura *, Targeting Nanomedicine to Brain Tumors: Latest Progress and Achievements, Current Pharmaceutical Design 2017; 23 (13) . https://dx.doi.org/10.2174/1381612822666161227153359
DOI https://dx.doi.org/10.2174/1381612822666161227153359 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Graphical Abstracts
Letters in Drug Design & Discovery Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective
Current Pharmaceutical Design Exploiting Apoptosis Pathways for the Treatment of Pancreatic Cancer
Current Signal Transduction Therapy Perfusion MRI of Brain Neoplams
Current Medical Imaging A Literature Review of the Recent Radiotherapy Clinical Trials in Pediatric Brain Tumors
Reviews on Recent Clinical Trials Aberrant Splicing, Hyaluronan Synthases and Intracellular Hyaluronan as Drivers of Oncogenesis and Potential Drug Targets
Current Cancer Drug Targets Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance
Current Drug Targets CB Receptor Ligands from Plants
Current Topics in Medicinal Chemistry Transplantation of Adipose Tissue-Derived Stem Cells for Treatment of Focal Cerebral Ischemia
Current Neurovascular Research Bitropic D3 Dopamine Receptor Selective Compounds s Potential Antipsychotics
Current Pharmaceutical Design Targeting the Folate Receptor: Effects of Conjugating Folic Acid to DOX Loaded Polymeric Micelles
Anti-Cancer Agents in Medicinal Chemistry In Vitro Regulatory Effect of Epididymal Serpin CRES on Protease Activity of Proprotein Convertase PC4/PCSK4
Current Molecular Medicine Identification of KEY lncRNAs and mRNAs Associated with Oral Squamous Cell Carcinoma Progression
Current Bioinformatics Quantitative Structure – Activity Relationship Study on Saponins as Cytotoxicity Enhancers
Letters in Drug Design & Discovery Preparation, Pharmacokinetic and Application of Gold Nanoclusters (AuNCs) in Tumor Treatment
Current Medicinal Chemistry Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?
Current Medicinal Chemistry Searching for Novel Cancer Chemopreventive Plants and their Products:The Genus Zanthoxylum
Current Drug Targets Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors
Current Topics in Medicinal Chemistry Glucose Transporters Regulation on Ischemic Brain: Possible Role as Therapeutic Target
Central Nervous System Agents in Medicinal Chemistry Recent Patents on Proteasome Inhibitors of Natural Origin
Recent Patents on Anti-Cancer Drug Discovery